GlassScriptPhysician profile
Thomas Mcgarry
NPI 1427045400
$79,561.03
in general payments reported to CMS, 2019-2025
10 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $10K · 2021: $15K · 2022: $6,582 · 2023: $12K · 2024: $7,200 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,820 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,970 · Food and Beverage: $767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,558.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,820.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,970.00 |
| Food and Beverage | $767.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $48,438.38 | 2019-2023 | Diamondback Peripheral, Diamondback Coronary |
| Abbott Laboratories | $30,625.58 | 2022-2025 | Diamondback Coronary |
| Pfizer INC. | $177.86 | 2025 | |
| Amgen INC. | $149.56 | 2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $132.64 | 2023 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.02 | 2023 | Lifevest |
| Janssen Pharmaceuticals, INC | $10.99 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Mcgarry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.